Survival following hospitalization with hepatocellular carcinoma among people notified with HBV or HCV in New South Wales, Australia 2000-2014

Waziry R¹, Grebely J¹, Amin J¹, Alavi M¹, Hajarizadeh B¹, George J², Matthews GV¹, Law M¹, Dore GJ¹
¹The Kirby Institute, UNSW Australia, Sydney, Australia, ²Storr Liver Centre, Westmead Millennium Institute for Medical Research and Westmead Hospital, University of Sydney, Sydney, Australia.

Introduction

• Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide
• Prognosis is poor with limited curative treatment options available
• Little is known about the recent trends in HCC in people with HBV or HCV in Australia

Aims

To assess trends in HCC survival in people with HBV or HCV in New South Wales (NSW), Australia

Methods

• Data on HBV (n=54,399) and HCV (n=96,908) notifications (1993 - 2012) were linked to:
  1. Admitted Patients Data Collection database (July 2000 - June 2014)
  2. National HIV/AIDS
  3. Births Deaths Marriages registries
• A case of HCC was defined by hospitalization with a HCC code (C22.0) as principal or additional diagnosis

Results

• Over the study period a total of 725 (1.3%) first HCC hospitalizations occurred among individuals with HBV and 1,309 (1.4%) among individuals with HCV
• Death occurred in 60.4% of HBV-HCC and 69.6% of HCV-HCC individuals
• Median age at death was 61 years (IQR=18) in HBV-HCC and 58 years (IQR=15) in HCV-HCC

Results

<table>
<thead>
<tr>
<th>Study period</th>
<th>n</th>
<th>Median survival time years (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCC-HBV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2000-2004</td>
<td>183</td>
<td>0.6 (0.39,1.28)</td>
</tr>
<tr>
<td>2005-2009</td>
<td>320</td>
<td>2.0 (1.10,3.07)</td>
</tr>
<tr>
<td>2010-2014</td>
<td>436</td>
<td>2.8 (1.54,5.54)</td>
</tr>
<tr>
<td>HCC-HCV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2000-2004</td>
<td>207</td>
<td>0.8 (0.45,1.33)</td>
</tr>
<tr>
<td>2005-2009</td>
<td>475</td>
<td>0.9 (0.72,1.24)</td>
</tr>
<tr>
<td>2010-2014</td>
<td>895</td>
<td>0.9 (0.67,1.18)</td>
</tr>
</tbody>
</table>

Table 1. Median survival time following first HCC hospitalization among those with HBV or HCV notification

Fig. 1. Kaplan Meier graphs of survival probability following first HCC hospitalization by study period among those with A) HBV notification and B) HCV notification in NSW, Australia 2000-2014

Fig. 2. Kaplan Meier graphs of survival probability following first HCC hospitalization by receiving potentially curative surgical procedures (liver resection, liver transplantation) among people with A) HBV notification and B) HCV notification in NSW, Australia 2000-2014

Fig. 3. Kaplan Meier graphs of survival probability following first HCC hospitalization by study period among those with HBV notification who received A) Potentially curative surgical procedures and B) No surgery in NSW, Australia 2000-2014

Fig. 4. Kaplan Meier graphs of survival probability following first HCC hospitalization by study period among those with HCV notification who received A) potentially curative surgical procedures and B) No surgery in NSW, Australia 2000-2014

Conclusion

In NSW, Australia between 2000-2014:
• Survival for HBV-HCC patients has improved considerably, suggesting an impact of more effective antiviral therapy from mid-2000s
• Survival for HBV-HCC patients improved for those with and without potentially curative surgical procedures
• In contrast, HCV-HCC survival is unchanged

Acknowledgements

This study was funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. The Kirby Institute is affiliated with the Faculty of Medicine, University of New South Wales. This study has received funding from the Sydney West Translational Cancer Research Centre (SW TARC) program “HOTTer West: HCC Outcome improvements through translational research in WESTern Sydney. This study is part of the Blood borne viruses and sexually transmissible infections Research, Strategic Interventions and Evaluation (BRISE) program, funded by the NSW Ministry of Health.